Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:13:06.334Z.
Calculation as of: 2026-10-06T19:13:06.334Z.
Quote observation: 2026-10-06T19:10:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 789431897149b7eb66dfe5c794b774a541b173055368acfdd0e045abcb2ddd87
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$261.62M
PE Ratio
N/A
TTM Avg
16.07
3Y Avg
13.93
5Y Avg
35.67
Market Cap
$262.00M
PE Ratio
N/A
TTM Avg
15.73
3Y Avg
15.73
5Y Avg
15.86
Market Cap
$262.65M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Palisade Bio, Inc. (PALI) | $261.78M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $261.62M | N/A | 16.07 | 13.93 | 35.67 |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $262.68M | N/A | 4.20 | 4.20 | 4.20 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.00M | N/A | 15.73 | 15.73 | 15.86 |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $262.65M | N/A | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.16M | N/A | N/A | N/A | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $265.65M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $258.00M | N/A | 14.47 | 14.47 | 17.60 |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.86M | N/A | 83.73 | 30.92 | 28.56 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $266.19M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.51
Forward EPS (Est.)
$-0.23
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2022-11-14 | 2.97 |
| 2022-11-11 | 2.97 |
| 2022-11-10 | 2.73 |
| 2022-11-09 | 2.54 |
| 2022-11-08 | 2.95 |
| 2022-11-07 | 3.14 |
| 2022-11-04 | 3.11 |
| 2022-11-03 | 3.03 |
| 2022-11-02 | 3.30 |
| 2022-11-01 | 3.36 |
| 2022-10-31 | 3.31 |
| 2022-10-28 | 3.44 |
| 2022-10-27 | 3.56 |
| 2022-10-26 | 3.55 |
| 2022-10-25 | 3.63 |
| 2022-10-24 | 3.63 |
| 2022-10-21 | 3.77 |
| 2022-10-20 | 3.87 |
| 2022-10-19 | 3.69 |
| 2022-10-18 | 3.80 |
| 2022-10-17 | 3.63 |
| 2022-10-14 | 3.44 |
| 2022-10-13 | 3.71 |
| 2022-10-12 | 3.34 |
| 2022-10-11 | 3.27 |
| 2022-10-10 | 3.75 |
| 2022-10-07 | 3.60 |
| 2022-10-06 | 4.10 |
| 2022-10-05 | 3.99 |
| 2022-10-04 | 4.15 |
| 2022-10-03 | 3.55 |
| 2022-09-30 | 3.59 |
| 2022-09-29 | 3.68 |
| 2022-09-28 | 3.93 |
| 2022-09-27 | 3.94 |
| 2022-09-26 | 4.06 |
| 2022-09-23 | 4.14 |
| 2022-09-22 | 4.48 |
| 2022-09-21 | 4.46 |
| 2022-09-20 | 4.54 |
| 2022-09-19 | 4.75 |
| 2022-09-16 | 5.08 |
| 2022-09-15 | 5.44 |
| 2022-09-14 | 5.99 |
| 2022-09-13 | 6.47 |
| 2022-09-12 | 5.46 |
| 2022-09-09 | 5.37 |
| 2022-09-08 | 5.30 |
| 2022-09-07 | 5.21 |
| 2022-09-06 | 4.93 |
| 2022-09-02 | 5.36 |
| 2022-09-01 | 5.19 |
| 2022-08-31 | 5.91 |
| 2022-08-30 | 6.02 |
| 2022-08-29 | 6.56 |
| 2022-08-26 | 6.68 |
| 2022-08-25 | 6.81 |
| 2022-08-24 | 6.35 |
| 2022-08-23 | 6.08 |
| 2022-08-22 | 5.85 |
| 2022-08-19 | 6.53 |
| 2022-08-18 | 5.95 |
| 2022-08-17 | 5.91 |
| 2022-08-16 | 7.53 |
